Belgian Blood Service Opts for INTERCEPT™
The Belgian Red Cross Flanders (RC-F), one of two major Red Cross blood services in Belgium, has signed a five-year agreement to purchase the INTERCEPT™ Blood System for platelets. INTERCEPT was selected by the RC-F thanks to the product’s accumulated haemovigilance and clinical data.
RC-F supplies approximately 37,000 platelet components to Flanders, the northern region of Belgium. The decision to proceed with the INTERCEPT Blood System is an important step towards making pathogen inactivation the standard of care in Europe. With approximately 65,000 platelet units produced annually, Belgium joins countries such as Switzerland, Iceland and Kuwait in making pathogen inactivated blood components generally available for all patients.